Abstract
Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Protein & Peptide Letters
Title:Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Volume: 20 Issue: 8
Author(s): Shuang- Yu Lv, Yan Jie Yang, Shangyu Hong, Ning- Bo Wang, Yao- Jun Qin, Wei- Xin Li and Qiang Chen
Affiliation:
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Abstract: Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Export Options
About this article
Cite this article as:
Lv Yu Shuang-, Yang Jie Yan, Hong Shangyu, Wang Bo Ning-, Qin Jun Yao-, Li Xin Wei- and Chen Qiang, Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice, Protein & Peptide Letters 2013; 20 (8) . https://dx.doi.org/10.2174/0929866511320080010
DOI https://dx.doi.org/10.2174/0929866511320080010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Therapeutic Targets in Cirrhotic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Non-ambient Conditions in the Investigation and Manufacturing of Drug Forms
Current Pharmaceutical Design An Improved Synthesis of m-Hydroxymexiletine, a Potent Mexiletine Metabolite
Drug Metabolism Letters GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry The Management and Outcomes of Pharmacological Treatments for Tinnitus
Current Neuropharmacology Cyclodextrin Based Nanosponges: A Multidimensional Drug Delivery System and its Biomedical Applications
Current Drug Delivery Adverse Drug Reactions in Hospitals: A Narrative Review
Current Drug Safety Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Update of Targeted Therapy-Induced Hypertension: Basics for Non-Oncology Providers
Current Hypertension Reviews Vasopressin in Health and Disease with a Focus on Affective Disorders
Central Nervous System Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Beneficial Effects of Corn Silk on Metabolic Syndrome
Current Pharmaceutical Design Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Hypotensive Agents from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders CB1 Cannabinoid Antagonists: Structure-Activity Relationships and Potential Therapeutic Applications
Current Topics in Medicinal Chemistry Antioxidant, Antimicrobial Activity and Medicinal Properties of Grewia asiatica L.
Medicinal Chemistry